SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Expanded Access Policy
Diabetes
Products
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Rights Issue
Skip Navigation Links
Home
»
Investors
»
Press Releases
Diamyd Medical’s financial year comprises 1 September – 31 August.
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Data pager
Data pager
1
2
3
Show:
PageSizeComboBox
select
10
20
50
100
150
3 pages
Press Releases
Data pager
Data pager
1
2
3
Show:
PageSizeComboBox
select
10
20
50
100
150
3 pages
4/25/2025
Diamyd Medical’s pivotal Phase 3 Type 1 Diabetes trial clears second-to-last safety review ahead of early readout in March 2026
4/22/2025
Shareholders in Diamyd Medical, including the Chairman of the Board, have provided additional subscription commitments in the ongoing rights issue
4/21/2025
Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout
4/17/2025
The prevention trial DiaPrecise with Diamyd
®
clears first safety milestone
4/15/2025
Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment
4/14/2025
Diamyd Medical publishes prospectus with regards to the rights issue
4/9/2025
Quarterly Report 2 24/25
3/21/2025
Diamyd Medical announces additional subscription commitments for upcoming rights issue
3/19/2025
Diamyd Medical plans for GMP Certification in 2025
3/17/2025
Diamyd Medical highlights clinical benefits of C-peptide preservation at ATTD 2025
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
|
Expanded Access Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research